Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 27, 2023

SELL
$0.9 - $1.85 $3,231 - $6,643
-3,591 Reduced 51.57%
3,373 $6,000
Q4 2022

Feb 02, 2023

SELL
$0.64 - $1.99 $2,562 - $7,967
-4,004 Reduced 36.51%
6,964 $7,000
Q3 2022

Nov 04, 2022

BUY
$2.73 - $4.92 $29,942 - $53,962
10,968 New
10,968 $25,000
Q2 2022

Aug 03, 2022

SELL
$2.8 - $7.67 $803 - $2,201
-287 Closed
0 $0
Q1 2022

May 02, 2022

BUY
$6.01 - $8.54 $1,724 - $2,450
287 New
287 $1,000
Q1 2021

Apr 26, 2021

SELL
$6.73 - $13.87 $14,577 - $30,042
-2,166 Closed
0 $0
Q4 2020

Feb 02, 2021

SELL
$6.37 - $10.33 $11,637 - $18,872
-1,827 Reduced 45.76%
2,166 $15,000
Q3 2020

Oct 14, 2020

BUY
$4.58 - $10.95 $18,287 - $43,723
3,993 New
3,993 $32,000
Q1 2020

Apr 29, 2020

SELL
$2.91 - $8.7 $69,918 - $209,034
-24,027 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$2.81 - $9.21 $67,515 - $221,288
24,027 New
24,027 $209,000
Q3 2019

Oct 15, 2019

SELL
$3.33 - $4.93 $779 - $1,153
-234 Closed
0 $0
Q2 2019

Jul 26, 2019

BUY
$4.3 - $6.73 $1,006 - $1,574
234 New
234 $1,000
Q1 2019

Apr 18, 2019

SELL
$3.43 - $6.87 $469 - $941
-137 Closed
0 $0
Q4 2018

Jan 16, 2019

SELL
$2.69 - $6.71 $146,346 - $365,050
-54,404 Reduced 99.75%
137 $0
Q3 2018

Oct 23, 2018

BUY
$6.5 - $8.37 $182,084 - $234,468
28,013 Added 105.6%
54,541 $354,000
Q2 2018

Jul 30, 2018

BUY
$7.27 - $21.88 $165,421 - $497,857
22,754 Added 602.91%
26,528 $203,000
Q1 2018

Apr 26, 2018

BUY
$13.4 - $28.4 $13,788 - $29,223
1,029 Added 37.49%
3,774 $84,000
Q4 2017

Jan 10, 2018

BUY
$12.52 - $17.82 $34,367 - $48,915
2,745
2,745 $34,000

Others Institutions Holding JNCE

About Jounce Therapeutics, Inc.


  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.